Survival from melanoma of the skin in England and Wales up to 2001

Por Ottensmeier, C H, Gore, M
Publicado em 2008

Absence of constitutive EGF receptor activation in ovarian cancer cell lines.

Por Ottensmeier, C., Swanson, L., Strobel, T., Druker, B., Niloff, J., Cannistra, S. A.
Publicado em 1996

Serum is not required for ex vivo IFN-γ ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program

Por Mander, A., Gouttefangeas, C., Ottensmeier, C., Welters, M. J. P., Low, L., van der Burg, S. H., Britten, C. M.
Publicado em 2010

Immunocytochemical assessment of bone marrow aspirates for monitoring response to chemotherapy in small-cell lung cancer patients

Por Pelosi, G, Pasini, F, Ottensmeier, C, Pavanel, F, Bresaola, E, Bonetti, A, Fraggetta, F, Terzi, A, Iannucci, A, Cetto, G L
Publicado em 1999

Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma

Por Matthews, LH McCormick, Noble, F, Tod, J, Jaynes, E, Harris, S, Primrose, J N, Ottensmeier, C, Thomas, G J, Underwood, T J
Publicado no Br J Cancer (2015)

Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma

Por McCormick Matthews, L H, Noble, F, Tod, J, Jaynes, E, Harris, S, Primrose, J N, Ottensmeier, C, Thomas, G J, Underwood, T J
Publicado no Br J Cancer (2015)

Response definition criteria for ELISPOT assays revisited

Por Moodie, Z., Price, L., Gouttefangeas, C., Mander, A., Janetzki, S., Löwer, M., Welters, M. J. P., Ottensmeier, C., van der Burg, S. H., Britten, Cedrik M.
Publicado em 2010

Vinflunine – an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study

Por Bennouna, J, Breton, J-L, Tourani, J-M, Ottensmeier, C, O'Brien, M, Kosmidis, P, Huat, T E, Pinel, M-C, Colin, C, Douillard, J-Y
Publicado em 2006

FOXO3 expression during colorectal cancer progression: biomarker potential reflects a tumour suppressor role

Por Bullock, M D, Bruce, A, Sreekumar, R, Curtis, N, Cheung, T, Reading, I, Primrose, J N, Ottensmeier, C, Packham, G K, Thomas, G, Mirnezami, A H
Publicado em 2013

Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab

Por Hardy-Werbin, M., Arpí, O., Taus, A., Rocha, P., Joseph-Pietras, D., Nolan, L., Danson, S., Griffiths, R., Lopez-Botet, M., Rovira, A., Albanell, J., Ottensmeier, C. H., Arriola, E.
Publicado no Oncoimmunology (2017)

Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer

Por Ward, M J, Thirdborough, S M, Mellows, T, Riley, C, Harris, S, Suchak, K, Webb, A, Hampton, C, Patel, N N, Randall, C J, Cox, H J, Jogai, S, Primrose, J, Piper, K, Ottensmeier, C H, King, E V, Thomas, G J
Publicado em 2014

Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies

Por Eisen, T, Marais, R, Affolter, A, Lorigan, P, Robert, C, Corrie, P, Ottensmeier, C, Chevreau, C, Chao, D, Nathan, P D, Jouary, T, Harries, M, Negrier, S, Montegriffo, E, Ahmad, T, Gibbens, I, James, M G, Strauss, U P, Prendergast, S, Gore, M E
Publicado em 2011

Melanoma sentinel node biopsy and prediction models for relapse and overall survival

Por Mitra, A, Conway, C, Walker, C, Cook, M, Powell, B, Lobo, S, Chan, M, Kissin, M, Layer, G, Smallwood, J, Ottensmeier, C, Stanley, P, Peach, H, Chong, H, Elliott, F, Iles, M M, Nsengimana, J, Barrett, J H, Bishop, D T, Newton-Bishop, J A
Publicado em 2010

A randomised, phase II study of intetumumab, an anti-α(v)-integrin mAb, alone and with dacarbazine in stage IV melanoma

Por O'Day, S, Pavlick, A, Loquai, C, Lawson, D, Gutzmer, R, Richards, J, Schadendorf, D, Thompson, J A, Gonzalez, R, Trefzer, U, Mohr, P, Ottensmeier, C, Chao, D, Zhong, B, de Boer, C J, Uhlar, C, Marshall, D, Gore, M E, Lang, Z, Hait, W, Ho, P
Publicado em 2011

The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8(+) T lymphocytes by structural and functional assays

Por Britten, C. M., Gouttefangeas, C., Welters, M. J. P., Pawelec, G., Koch, S., Ottensmeier, C., Mander, A., Walter, S., Paschen, A., Müller-Berghaus, J., Haas, I., Mackensen, A., Køllgaard, T., thor Straten, P., Schmitt, M., Giannopoulos, K., Maier, R., Veelken, H., Bertinetti, C., Konur, A., Huber, C., Stevanović, S., Wölfel, T., van der Burg, S. H.
Publicado em 2007

OS2.2 Highly personalized peptide vaccination for patients with newly diagnosed glioblastoma: the GAPVAC trial

Por Dietrich, P, Wick, W, Hilf, N, Frenzel, K, Gouttefangeas, C, Platten, M, thor Straten, P, Lassen, U, Rodon, J, Bukur, V, Admon, A, van der Burg, S H, von Deimling, A, Kroep, J R, Martinez-Ricarte, F, Okada, H, Ottensmeier, C H, Ponsati, B, Poulsen, H S, Stevanovic, S, Tabatabai, G, Rammensee, H, Sahin, U, Singh-Jasuja, H
Publicado no Neuro Oncol (2018)

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

Por Corrie, P G, Marshall, A, Nathan, P D, Lorigan, P, Gore, M, Tahir, S, Faust, G, Kelly, C G, Marples, M, Danson, S J, Marshall, E, Houston, S J, Board, R E, Waterston, A M, Nobes, J P, Harries, M, Kumar, S, Goodman, A, Dalgleish, A, Martin-Clavijo, A, Westwell, S, Casasola, R, Chao, D, Maraveyas, A, Patel, P M, Ottensmeier, C H, Farrugia, D, Humphreys, A, Eccles, B, Young, G, Barker, E O, Harman, C, Weiss, M, Myers, K A, Chhabra, A, Rodwell, S H, Dunn, J A, Middleton, M R
Publicado no Ann Oncol (2018)